AbbVie Files Rinvoq with FDA for Severe Alopecia Areata

AbbVie filed a supplemental New Drug Application with the FDA on April 28, 2026 seeking approval of upadacitinib, sold under the brand name Rinvoq, for adults and adolescents 12 and older with severe alopecia areata. The submission is built on two registrational Phase 3 trials in which the once-daily oral JAK1 inhibitor became the first drug in its class to hit complete scalp hair regrowth as a ranked secondary endpoint, raising the ceiling on what dermatologists can offer patients with one of the most psychologically corrosive skin conditions. ## A New Bar for the JAK Class in Alopecia Areata The UP-AA program enrolled 1,399 patients across 248 sites worldwide, randomizing patients ages 12 to 63 to placebo, 15 mg upadacitinib, or 30 mg upadacitinib once daily. The primary endpoint at week 24 was a Severity of Alopecia Tool (SALT) score of 20 or below, meaning at least 80 percent scalp hair coverage. In Study 1, 55.0 percent of the 30 mg arm and 45.2 percent of the 15 mg arm reached that threshold, compared with 1.5 percent on placebo. Study 2 produced 54.3 percent and 44.6 percent for the same doses, against 3.4 percent placebo, according to AbbVie's [August 2025 topline release](https://news.abbvie.com/2025-08-21-AbbVie-Announces-Positive-Topline-Results-from-Second-Phase-3-UP-AA-Trial-Evaluating-Upadacitinib-RINVOQ-R-for-Alopecia-Areata). The figure that separates upadacitinib from the two oral JAK inhibitors already approved for the indication, baricitinib and ritlecitinib, is the SALT = 0 result. In Study 1, 20.3 percent of the 30 mg arm achieved complete scalp regrowth at week 24. Study 2 hit 22.5 percent. AbbVie says this makes upadacitinib the first JAK inhibitor to meet complete regrowth as a ranked secondary endpoint, a structural distinction that matters for both the label language and how clinicians will compare the three drugs. Alopecia areata affects roughly 7 million people in the United States, and severe forms, including alopecia totalis and alopecia universalis, have historically had no consistently effective systemic option until the JAK class arrived in 2022. Recent investigational efforts have explored alternative immune mechanisms, including [Treg-modulating biologics like rezpegaldesleukin](https://skincareful.care/science/rezpegaldesleukin-alopecia-areata-treg-2026/), and [topical PROTAC degraders for androgenetic alopecia](https://skincareful.care/science/gt20029-topical-protac-aga-phase2-results/), each targeting a different node in the hair-loss biology. ## How Does Rinvoq Compare to the Other JAK Inhibitors Approved for Alopecia Areata? Baricitinib (Olumiant), approved in June 2022, was the first oral systemic. Ritlecitinib (Litfulo), approved in June 2023, followed for patients 12 and older. Both produce meaningful regrowth, but neither hit complete scalp coverage at the rates seen in UP-AA. Upadacitinib's SALT = 0 numbers at 30 mg, in the low-20-percent range, are the highest reported in a Phase 3 alopecia areata trial to date. The trade-off is the safety profile, which is consistent with the JAK class. AbbVie's Phase 3 data showed serious infections in 0.7 percent (15 mg) and 1.0 percent (30 mg) of patients versus none on placebo, with no adjudicated major adverse cardiovascular events, malignancies, or deaths over the 24-week induction period. The most common treatment-emergent adverse events were acne, nasopharyngitis, and upper respiratory tract infection. Upadacitinib carries the FDA's class-wide boxed warning for serious infections, malignancies, thrombosis, and cardiovascular risk. ## What Does This Mean for Skincare-Conscious Readers? Alopecia areata sits at the boundary of dermatology and skincare culture, and the language patients use to describe it, including diffuse shedding, patchy loss, and scalp scarring, increasingly overlaps with the broader conversation around hair density, postpartum hair loss, and chronic telogen effluvium. A more effective oral systemic does not change topical or in-clinic options for these adjacent conditions, but it does signal where the research dollars are flowing. JAK inhibition is now mature enough that pharmaceutical companies are running positioning trials, and the clinical bar for what counts as a strong regrowth result is rising. For readers tracking the science, the more interesting question is whether selective JAK1 inhibition (upadacitinib) outperforms broader JAK1/2 inhibition (baricitinib) and JAK3/TEC family inhibition (ritlecitinib) on regrowth depth and durability. UP-AA suggests it might, though no head-to-head trial has been run. ## When Could Rinvoq Be Approved for Alopecia Areata? The FDA has not announced a target action date for the upadacitinib alopecia areata sNDA. Standard agency review timelines run roughly 10 months for non-priority applications, which would put a possible decision in early 2027. AbbVie has also submitted to the European Medicines Agency, with a separate review timeline. Until then, the existing JAK inhibitors remain the only oral systemic options, and patient access continues to depend largely on insurance coverage and specialty pharmacy availability. This story will be updated as the FDA confirms its review timeline and AbbVie publishes 52-week durability and long-term safety data from the [UP-AA program](https://news.abbvie.com/2026-04-28-AbbVie-Submits-Application-to-FDA-for-Upadacitinib-RINVOQ-R-for-Adults-and-Adolescents-with-Severe-Alopecia-Areata).